Conditions: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Keywords: GRN1005 ANG1005 LRP-1 Targeted Therapy Brain Tumor Blood Brain Barrier Peptide-Drug Conjugate (PDC) Brain Metastases Paclitaxel Taxol NSCLC Non-Small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 16
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).

Detailed description:

Arms:
arm 1: GRN1005 alone

Interventions: intervention 1: GRN1005
Intervention descriptions: intervention 1: 650 mg/m2 IV every 3 weeks

Protocol document: